소비자 직접 의뢰(DTC) 유전자 검사 시장 규모, 점유율 및 동향 분석 보고서 : 검사 유형별, 기술별, 유통 채널별, 지역별 및 부문별 예측(2026-2033년)

Direct-to-Consumer Genetic Testing Market Summary

The global direct-to-consumer genetic testing market size was estimated at USD 2.32 billion in 2025 and is projected to reach USD 6.80 billion by 2033, growing at a CAGR of 14.0% from 2026 to 2033. The market growth is driven by the prevalence of chronic diseases, a stronger emphasis on preventive and personalized healthcare, and continuous advancements in diagnostics and testing.

Moreover, the integration of DTC genetic testing with digital health platforms and telemedicine is creating new growth opportunities by enabling remote interpretation, personalized consultations, and continuous health monitoring.

The growth of the direct-to-consumer genetic testing market is driven by the prevalence of chronic diseases, which require early risk assessment and preventive care strategies. Chronic conditions necessitate continuous monitoring, creating a strong demand for accessible, at-home genetic testing solutions that enable individuals to evaluate disease predisposition. According to the World Health Organization, non-communicable diseases account for over 74% of global deaths, underscoring the importance of early detection and preventive healthcare. Direct-to-consumer genetic testing allows individuals to assess genetic susceptibility to conditions such as BRCA-related breast cancer, cardiovascular diseases, and metabolic disorders, enabling timely lifestyle modifications and informed medical decisions. This trend is accelerating the adoption of at-home genetic testing solutions and reinforcing the role of the direct-to-consumer genetic testing market in preventive healthcare.

The growing emphasis on preventive and personalized healthcare is a major driver of the direct-to-consumer genetic testing market. Healthcare systems are shifting from a reactive, treatment-focused approach to a proactive model that prioritizes early risk identification and individualized care. This shift is encouraging individuals to seek insights into their genetic predisposition to chronic conditions such as cardiovascular diseases, cancer, and metabolic disorders before symptoms appear. For instance, in 2025, Targeted Genomics received U.S. FDA 510(k) clearance for its direct-to-consumer GlutenID test. The test analyzes key genetic markers using at-home saliva samples to assess susceptibility to celiac disease. The test delivers rapid, high-throughput, and easily interpretable results, supporting large-scale genetic screening. This advancement enhances accessibility, reliability, and user comprehension of genetic risk assessment, thereby accelerating the adoption of at-home genetic testing solutions and supporting the growth of the direct-to-consumer genetic testing market.

Global Direct-to-Consumer Genetic Testing Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the direct-to-consumer genetic testing market report based on test type, technology, distribution channel, and region:

• Test Type Outlook (Revenue, USD Million, 2021 - 2033)
• Nutrigenomics Testing
• Predictive Testing
• Carrier Testing
• Others
• Technology Outlook (Revenue, USD Million, 2021 - 2033)
• Whole Genome Sequencing
• Single Nucleotide Polymorphism Chips
• Targeted Analysis
• Others
• Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
• Online Platform
• OTC
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Spain
  • Italy
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • Thailand
  • South Korea
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Test Type
  • 1.2.2. Technology
  • 1.2.3. Distribution Channel
  • 1.2.4. Regional scope
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
    • 1.5.4.1. Data for primary interviews in North America
    • 1.5.4.2. Data for primary interviews in Europe
    • 1.5.4.3. Data for primary interviews in the Asia Pacific
    • 1.5.4.4. Data for primary interviews in Latin America
    • 1.5.4.5. Data for Primary interviews in MEA
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Validation
• 1.8. Model Details
• 1.9. Commodity flow analysis (Model 1)
  • 1.9.1. Approach 1: Commodity flow approach
  • 1.9.2. Volume price analysis (Model 2)
  • 1.9.3. Approach 2: Volume price analysis
• 1.10. List of Secondary Sources
• 1.11. List of Primary Sources
• 1.12. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
  • 2.2.1. Test Type
  • 2.2.2. Technology
  • 2.2.3. Distribution Channel
  • 2.2.4. Regional outlook
• 2.3. Competitive Landscape Snapshot

Chapter 3. Direct-to-Consumer Genetic Testing Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Rising prevalence of chronic diseases,
    • 3.2.1.2. Stronger emphasis on preventive and personalized healthcare
    • 3.2.1.3. Continuous advancements in diagnostics and testing.
    • 3.2.1.4. Integration of DTC genetic testing with digital health platforms and telemedicine
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Data privacy and security concerns
    • 3.2.2.2. Limited clinical validity and risk of misinterpretation
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis
  • 3.3.3. Pipeline Analysis
  • 3.3.4. Patent Expiry Analysis
  • 3.3.5. Pricing Analysis

Chapter 4. Direct-to-Consumer Genetic Testing Market: Test Type Estimates & Trend Analysis

• 4.1. Test type Market Share, 2025 & 2033
• 4.2. Segment Dashboard
• 4.3. Global In-vitro Diagnostics Enzymes Market by Test type Outlook
• 4.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
• 4.5. Nutrigenomics Testing
  • 4.5.1. Nutrigenomics Testing Market estimates and forecasts 2021 to 2033 (USD million)
• 4.6. Predictive Testing
• 4.7. Predictive Testing Market estimates and forecasts 2021 to 2033 (USD Million)
• 4.8. Carrier Testing
  • 4.8.1. Carrier Testing Market estimates and forecasts 2021 to 2033 (USD Million)
• 4.9. Others
  • 4.9.1. Others Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. Direct-to-Consumer Genetic Testing Market: Technology Business Analysis

• 5.1. Technology Market Share, 2025 & 2033
• 5.2. Technology Segment Dashboard
• 5.3. Global Direct-to-Consumer Genetic Testing Market by Technology Outlook
• 5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
• 5.5. Whole Genome Sequencing
  • 5.5.1. Whole Genome Sequencing Market estimates and forecasts 2021 to 2033 (USD million)
• 5.6. Single Nucleotide Polymorphism Chips
  • 5.6.1. Single Nucleotide Polymorphism Chips Market estimates and forecasts 2021 to 2033 (USD Million)
• 5.7. Targeted Analysis
  • 5.7.1. Targeted Market Analysis and forecasts 2021 to 2033 (USD Million)
• 5.8. Others
  • 5.8.1. Others Market estimates and forecasts 2021 to 2033

Chapter 6. Direct-to-Consumer Genetic Testing Market: Distribution Channel Estimates & Trend Analysis

• 6.1. Distribution Channel Market Share, 2025 & 2033
• 6.2. Segment Dashboard
• 6.3. Global Direct-to-Consumer Genetic Testing Market by Distribution Channel Outlook
• 6.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
• 6.5. Online Platform
  • 6.5.1. Online Platform Market estimates and forecasts 2021 to 2033 (USD million)
• 6.6. OTC
  • 6.6.1. OTC Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. Direct-to-Consumer Genetic Testing Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Share Analysis, 2025 & 2033
• 7.2. Regional Market Dashboard
• 7.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
• 7.4. North America
  • 7.4.1. North America Direct-to-Consumer Genetic Testing Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
  • 7.4.2. U.S.
    • 7.4.2.1. Key Country Dynamics
    • 7.4.2.2. Target Disease Prevalence
    • 7.4.2.3. Regulatory Framework
    • 7.4.2.4. Reimbursement Framework
    • 7.4.2.5. U.S. Direct-to-Consumer Genetic Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.3. Canada
    • 7.4.3.1. Key Country Dynamics
    • 7.4.3.2. Target Disease Prevalence
    • 7.4.3.3. Regulatory Framework
    • 7.4.3.4. Reimbursement Framework
    • 7.4.3.5. Canada Direct-to-Consumer Genetic Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.4. Mexico
    • 7.4.4.1. Key Country Dynamics
    • 7.4.4.2. Target Disease Prevalence
    • 7.4.4.3. Regulatory Framework
    • 7.4.4.4. Reimbursement Framework
    • 7.4.4.5. Mexico Direct-to-Consumer Genetic Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.5. Europe
  • 1.1.1. Europe Direct-to-Consumer Genetic Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.1. UK
    • 7.5.1.1. Key Country Dynamics
    • 7.5.1.2. Target Disease Prevalence
    • 7.5.1.3. Regulatory Framework
    • 7.5.1.4. Reimbursement Framework
    • 7.5.1.5. UK Direct-to-Consumer Genetic Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.2. Germany
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Target Disease Prevalence
    • 7.5.2.3. Regulatory Framework
    • 7.5.2.4. Reimbursement Framework
    • 7.5.2.5. Germany Direct-to-Consumer Genetic Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.3. France
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Target Disease Prevalence
    • 7.5.3.3. Regulatory Framework
    • 7.5.3.4. Reimbursement Framework
    • 7.5.3.5. France Direct-to-Consumer Genetic Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.4. Italy
    • 7.5.4.1. Key Country Dynamics
    • 7.5.4.2. Target Disease Prevalence
    • 7.5.4.3. Regulatory Framework
    • 7.5.4.4. Reimbursement Framework
    • 7.5.4.5. Italy Direct-to-Consumer Genetic Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.5. Spain
    • 7.5.5.1. Key Country Dynamics
    • 7.5.5.2. Target Disease Prevalence
    • 7.5.5.3. Regulatory Framework
    • 7.5.5.4. Reimbursement Framework
    • 7.5.5.5. Spain Direct-to-Consumer Genetic Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.6. Denmark
    • 7.5.6.1. Key Country Dynamics
    • 7.5.6.2. Target Disease Prevalence
    • 7.5.6.3. Regulatory Framework
    • 7.5.6.4. Reimbursement Framework
    • 7.5.6.5. Denmark Direct-to-Consumer Genetic Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.7. Sweden
    • 7.5.7.1. Key Country Dynamics
    • 7.5.7.2. Target Disease Prevalence
    • 7.5.7.3. Regulatory Framework
    • 7.5.7.4. Reimbursement Framework
    • 7.5.7.5. Sweden Direct-to-Consumer Genetic Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.8. Norway
    • 7.5.8.1. Key Country Dynamics
    • 7.5.8.2. Target Disease Prevalence
    • 7.5.8.3. Regulatory Framework
    • 7.5.8.4. Reimbursement Framework
    • 7.5.8.5. Norway Direct-to-Consumer Genetic Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.6. Asia Pacific
  • 7.6.1. Asia Pacific Direct-to-Consumer Genetic Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.2. Japan
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Target Disease Prevalence
    • 7.6.2.3. Regulatory Framework
    • 7.6.2.4. Reimbursement Framework
    • 7.6.2.5. Japan Direct-to-Consumer Genetic Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.3. China
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Target Disease Prevalence
    • 7.6.3.3. Regulatory Framework
    • 7.6.3.4. Reimbursement Framework
    • 7.6.3.5. China Direct-to-Consumer Genetic Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.4. India
    • 7.6.4.1. Key Country Dynamics
    • 7.6.4.2. Target Disease Prevalence
    • 7.6.4.3. Regulatory Framework
    • 7.6.4.4. Reimbursement Framework
    • 7.6.4.5. India Direct-to-Consumer Genetic Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.5. Australia
    • 7.6.5.1. Key Country Dynamics
    • 7.6.5.2. Target Disease Prevalence
    • 7.6.5.3. Regulatory Framework
    • 7.6.5.4. Reimbursement Framework
    • 7.6.5.5. Australia Direct-to-Consumer Genetic Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.6. South Korea
    • 7.6.6.1. Key Country Dynamics
    • 7.6.6.2. Target Disease Prevalence
    • 7.6.6.3. Regulatory Framework
    • 7.6.6.4. Reimbursement Framework
    • 7.6.6.5. South Korea Direct-to-Consumer Genetic Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.7. Thailand
    • 7.6.7.1. Key Country Dynamics
    • 7.6.7.2. Target Disease Prevalence
    • 7.6.7.3. Regulatory Framework
    • 7.6.7.4. Reimbursement Framework
    • 7.6.7.5. Thailand Direct-to-Consumer Genetic Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.8. Latin America
  • 7.6.9. Latin America Direct-to-Consumer Genetic Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.10. Brazil
    • 7.6.10.1. Key Country Dynamics
    • 7.6.10.2. Target Disease Prevalence
    • 7.6.10.3. Regulatory Framework
    • 7.6.10.4. Reimbursement Framework
    • 7.6.10.5. Brazil Direct-to-Consumer Genetic Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.11. Argentina
    • 7.6.11.1. Key Country Dynamics
    • 7.6.11.2. Target Disease Prevalence
    • 7.6.11.3. Regulatory Framework
    • 7.6.11.4. Reimbursement Framework
    • 7.6.11.5. Argentina Direct-to-Consumer Genetic Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.7. Middle East and Africa
  • 7.7.1. Middle East and Africa Direct-to-Consumer Genetic Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7.2. South Africa
    • 7.7.2.1. Key Country Dynamics
    • 7.7.2.2. Target Disease Prevalence
    • 7.7.2.3. Regulatory Framework
    • 7.7.2.4. Reimbursement Framework
    • 7.7.2.5. South Africa Direct-to-Consumer Genetic Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7.3. Saudi Arabia
    • 7.7.3.1. Key Country Dynamics
    • 7.7.3.2. Target Disease Prevalence
    • 7.7.3.3. Regulatory Framework
    • 7.7.3.4. Reimbursement Framework
    • 7.7.3.5. Saudi Arabia Direct-to-Consumer Genetic Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7.4. UAE
    • 7.7.4.1. Key Country Dynamics
    • 7.7.4.2. Target Disease Prevalence
    • 7.7.4.3. Regulatory Framework
    • 7.7.4.4. Reimbursement Framework
    • 7.7.4.5. UAE Direct-to-Consumer Genetic Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7.5. Kuwait
    • 7.7.5.1. Key Country Dynamics
    • 7.7.5.2. Target Disease Prevalence
    • 7.7.5.3. Regulatory Framework
    • 7.7.5.4. Reimbursement Framework
    • 7.7.5.5. Kuwait Direct-to-Consumer Genetic Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Participant Overview
• 8.2. Company Market Position Analysis
• 8.3. Company Categorization
• 8.4. Strategy Mapping
• 8.5. Company Profiles/Listing
  • 8.5.1. 23andMe
    • 8.5.1.1. Overview
    • 8.5.1.2. Financial Performance
    • 8.5.1.3. Product Benchmarking
    • 8.5.1.4. Strategic Initiatives
  • 8.5.2. Family Tree DNA.
    • 8.5.2.1. Overview
    • 8.5.2.2. Financial Performance
    • 8.5.2.3. Product Benchmarking
    • 8.5.2.4. Strategic Initiatives
  • 8.5.3. Ancestry.
    • 8.5.3.1. Overview
    • 8.5.3.2. Financial Performance
    • 8.5.3.3. Product Benchmarking
    • 8.5.3.4. Strategic Initiatives
  • 8.5.4. Myriad Genetics, Inc.
    • 8.5.4.1. Overview
    • 8.5.4.2. Financial Performance
    • 8.5.4.3. Product Benchmarking
    • 8.5.4.4. Strategic Initiatives
  • 8.5.5. Genesis HealthCare.
    • 8.5.5.1. Overview
    • 8.5.5.2. Financial Performance
    • 8.5.5.3. Product Benchmarking
    • 8.5.5.4. Strategic Initiatives
  • 8.5.6. EasyDNA
    • 8.5.6.1. Overview
    • 8.5.6.2. Financial Performance
    • 8.5.6.3. Product Benchmarking
    • 8.5.6.4. Strategic Initiatives
  • 8.5.7. Veritas
    • 8.5.7.1. Overview
    • 8.5.7.2. Financial Performance
    • 8.5.7.3. Product Benchmarking
    • 8.5.7.4. Strategic Initiatives
  • 8.5.8. Full Genomes Corporation, Inc
    • 8.5.8.1. Overview
    • 8.5.8.2. Financial Performance
    • 8.5.8.3. Product Benchmarking
    • 8.5.8.4. Strategic Initiatives
  • 8.5.9. Living DNA Ltd.
    • 8.5.9.1. Overview
    • 8.5.9.2. Financial Performance
    • 8.5.9.3. Product Benchmarking
    • 8.5.9.4. Strategic Initiatives
  • 8.5.10. Color Health, Inc.
    • 8.5.10.1. Overview
    • 8.5.10.2. Financial Performance
    • 8.5.10.3. Product Benchmarking
    • 8.5.10.4. Strategic Initiatives